Skip to main content
Intensive Care Medicine Experimental
Fig. 5 | Intensive Care Medicine Experimental

Fig. 5

From: Identifying a target group for selenium supplementation in high-risk cardiac surgery: a secondary analysis of the SUSTAIN CSX trial

Fig. 5

Subgroup III and IV. A In patients with selenium deficiency at baseline (defined as values < 70 µg/l), selenium treatment (blue) increased serum selenium, selenoprotein P (SELENOP) and glutathione peroxidase 3 (GPx3) activity (III). B In patients with GPx3 activity < 250 U/l at baseline, selenium treatment again successfully increased all biomarkers, including GPx3 (IV). C Subgroups III and IV are contrasted with the respective remainder of each patient population. High GPx3 activity remained unchanged throughout the observation period independent of selenium supplementation. For better presentation, error bars were removed, and connecting lines were inserted. Gray coloration indicates values below the lower reference limit (selenium and SELENOP) and above the upper reference limit (GPx3). Reference ranges were used as published elsewhere. Asterisks (*) indicate statistical significance, and waves (≈) indicate a trend. BL baseline, ICU intensive care unit

Back to article page